Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on July 1, 2019, covering events occurring on June 28, 2019. The company is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on the NASDAQ Capital Market under the symbol "LIFE". The filing primarily addresses changes to the composition of the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Appointments: The Board appointed Jane A. Gross, Ph.D. (Class II director) and Svetlana Lucas, Ph.D. (Class III director), effective June 28, 2019.
- Director Resignation: John D. Mendlein, Ph.D., resigned from the Board effective June 28, 2019. The resignation was not due to any disagreement with management regarding operations or policies.
- Continued Engagement: Dr. Mendlein will continue to serve as a strategic advisor under an existing agreement dated November 1, 2017.
Compensation and Governance Details
As non-employee directors, Drs. Gross and Lucas will receive cash and equity compensation per the company's policy. Each was granted an option to purchase 32,000 shares of Common Stock (on a pre-reverse stock split basis). The exercise price is set at the closing price on June 28, 2019, with vesting occurring in equal monthly installments over three years, contingent on continued service. Both new directors entered into standard indemnification agreements.
Investor Verification Checklist
- Verify the closing stock price on June 28, 2019, to determine the exercise price for the new director stock options.
- Review the attached press release (Exhibit 99.1) for additional context on the new directors' backgrounds.
- Confirm the terms of the Strategic Advisor Agreement with Dr. Mendlein to understand the scope of his continued involvement.
- Check subsequent filings for the formal election of these directors at the 2020 and 2021 annual meetings.